

At the conclusion of the **Nuclear Medicine** program, the learner will be able to:

- Discuss challenges and opportunities of PSMA Theranostics
- Identify protocols for patient selection criteria
- Cite evidence of improved response rates of radio ligand therapy (RLT) of metastatic castration-resistant prostate cancer using Lu-labeled PSMA ligands
- State strengths and weaknesses of FDG PET/CT for staging of breast cancer
- Utilize FDG PET/CT to measure breast cancer treatment response